C91.52 Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse

Name of the Condition

• Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse
• ICD-10 Code: C91.52

Summary

Adult T-cell lymphoma/leukemia (HTLV-1-associated), in relapse, is a rare, aggressive cancer of T lymphocytes caused by the human T-cell lymphotropic virus type 1 (HTLV-1). It involves the uncontrolled proliferation of abnormal T cells, which may affect the blood, lymph nodes, skin, or other organs. The condition typically presents as leukemia (with high circulating cancer cells) or lymphoma (with tissue tumors) and is endemic in regions like Japan, the Caribbean, and parts of Africa. This code specifically denotes cases where the disease has reactivated after a period of remission.

Causes

The primary cause is infection with the HTLV-1 virus, which integrates into T-cell DNA and disrupts normal cell regulation. Genetic mutations in T cells, triggered by the virus, lead to uncontrolled growth. Transmission occurs through blood transfusions, shared needles, sexual contact, or mother-to-child transmission (e.g., breastfeeding). Not all infected individuals develop the disease, suggesting additional host or environmental factors may contribute.

Risk Factors

• Infection with HTLV-1 virus
• Residence in or travel to endemic regions (e.g., Japan, Caribbean, Africa)
• Prolonged breastfeeding in infants of infected mothers
• Blood transfusion or organ transplant from an infected donor

Symptoms

Symptoms may include fatigue, fever, weight loss, enlarged lymph nodes, skin lesions, or organ involvement (e.g., liver, spleen). In relapse, symptoms may reappear or worsen, depending on the site of recurrence.

Diagnosis

Diagnosis involves blood tests (e.g., complete blood count, flow cytometry), imaging (e.g., CT scans), and tissue biopsy. HTLV-1 serology confirms viral infection, while molecular testing detects clonal T-cell populations. Relapse is confirmed by recurrence of abnormal cells or clinical symptoms after remission.

Treatment Options

Treatment may include chemotherapy, targeted therapy, or stem cell transplantation. Management focuses on controlling the disease and addressing relapse-specific symptoms. Supportive care (e.g., infection prevention, symptom management) is also critical.

Prognosis and Follow-Up

Prognosis depends on disease extent, response to prior treatment, and overall health. Relapse may indicate a more aggressive course, requiring close monitoring. Follow-up includes regular blood work, imaging, and clinical assessments to detect recurrence early.

Complications

Complications may include severe infections, organ failure, or treatment-related toxicities. Relapse increases the risk of progressive disease or treatment resistance.

Lifestyle & Prevention

Prevention focuses on reducing HTLV-1 transmission (e.g., safe blood products, avoiding shared needles). For those with a history of the disease, maintaining overall health and adhering to follow-up care may help manage relapse risk.

When to Seek Professional Help

Seek care if symptoms reappear or worsen, especially after remission. Prompt evaluation is important for early intervention in relapse.

Tips for Medical Coders

Use C91.52 for adult T-cell lymphoma/leukemia (HTLV-1-associated) in relapse. Document clinical evidence of relapse (e.g., recurrence of symptoms, abnormal test results) to support coding. Ensure alignment with the patient’s current clinical status and prior treatment history.